IPCOR is excited to announce a second edition of the novel prostate cancer outcomes registry, housed in the School of Medicine under Professor David Galvin. With an investment of €2.5 million, Movember is the sole funder of this initiative, which aims to analyse clinical quality trends and drive improvements in prostate cancer care for men in major hospitals of Dublin and Galway. IPCOR is now a completely digital registry, based on a cloud-based Dacima environment implementing a smart and appropriate solution for abstraction of the multidisciplinary and extensive prostate cancer datasets.
In addition to collecting clinical data, IPCOR 2 will track patient-reported outcomes such as side effects and quality of life, and for the first time, it will collect biological samples, such as blood, urine, and tissue, to support groundbreaking research. Hospitals will be able to use IPCOR’s new electronic reporting system to access real-time patient data, helping doctors provide more personalized, responsive care and policymakers to address disparities in treatment access and outcomes. IPCOR 2’s data will shape the future of prostate cancer treatment, driving new discoveries and improving outcomes for Irish men.
Prostate cancer remains the most commonly diagnosed cancer in Irish men, affecting 1 in 8 men during their lifetime. IPCOR will play a crucial role in understanding trends and gaps in how prostate cancer is diagnosed, treated, and managed in Ireland.
The Lived Experiences Advisory Panel (LEAP) of men who have experienced diagnosis and treatment of prostate cancer is an extremely valuable resource for IPCOR. The LEAP group has co-developed the participant consent-taking and PROMs collection processes as well as reviewing all patient communication documents and advising on addition of standardised tools at various time points that address issues important to patients. 
The LEAP group has also initiated efforts to engage their caregivers and partners to further understand issues that affect household and personal relationships during the prostate cancer journey. IPCOR continues to work with its LEAP group to create a platform of available resources for men and connect with those suffering from the hidden disabilities associated with prostatic symptoms and interventions.
For collaborations and queries: ipcor@ucd.ie (www.ipcor.ie)
